Type II Diabetes
Conditions
Brief summary
Type 2 diabetes patients often do not reach desired control of glycemia despite guidance on changing lifestyle and diet as well as the use of conventional anti-diabetic medication. Parallely in recent years, an array of comparative clinical studies have demonstrated the anti-diabetic effect of more than 10 common spices and food products. Objectives: to evaluate whether proposing a choice of spices and foods products with hypoglycemic effect to diabetic patients can help better control diabetes.
Detailed description
Diabetic type II patients would be encouraged to eat what they like within a list of food products with hypoglycemic effect, at a similar dosage and preparation mode than the one in the reference clinical trials. This pilot project will be conducted as a randomized controlled trial with 2 arms over 12 weeks: 1. training patients about hypoglycemic spices and foods alongside their usual anti-diabetic treatment, versus usual anti-diabetic treatment alone. Expected results: Confirmation of the hypothesis that daily consuming spices and foods with hypoglycemic effect to diabetic patients can help better control diabetes.
Interventions
DIETARY_SUPPLEMENTHypoglycemic food group
A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
DIETARY_SUPPLEMENTControl group
The control group will receive only lifestyle and dietary recommendations.
Sponsors
Khon Kaen University
Antenna Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
At the first visit, patients will be randomly assigned to control group or intervention group.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes patients with poorly controlled glycemia, i.e. at least one of the following measurements: 1. Fasting plasma glucose (FPG) values ≥ 7.0 mmol/L (126 mg/dl), or 2-h post-load plasma glucose ≥ 11.1 mmol/L (200 mg/dl), or HbA1c \> 6.5% (48 mmol/mol); or a random blood glucose ≥ 11.1 mmol/L (200 mg/ dl), despite ≥ 3 months usual care (lifestyle + medication if applicable).
Exclusion criteria
1. Severe and unstable complications of diabetes: end-organ damage such as nephropathy, retinopathy, neuropathy, etc... 2. Patients with rapid insulin, 3. Any health condition that requires urgent attention, 4. Patients with a cognitive or sensory impairment that may prevent conducting the interview, 5. HbA1c \> 11.5% 6. Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease of ≥ 0.5mmol/L in FPG | 12 weeks | Percentage of patients in each group reaching a decrease of ≥ 0.5mmol/L in FPG over 12 weeks |
| Decrease of ≥ 0.5 points of percentage of HbA1c | 12 weeks | Percentage of patients in each group reaching a decrease of ≥ 0.5 points of percentage from the baseline value in HbA1c over 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Weight | 12 weeks | Mean change of weight \[kg\] over 12 weeks |
| Mean change of FPG | 12 weeks | Mean change of FPG e.g. differences between baseline values and values at 12 weeks |
| Blood pressure | 12 weeks | Mean change of systolic and diastolic blood pressure \[mmHg\] over 12 weeks |
| Mean change of HbA1c | 12 weeks | Mean change of HbA1c e.g. differences between baseline values and values at 12 weeks |
| Target glycemia | 12 weeks | Proportion of patients in each group reaching target glycemia over 12 weeks |
Contacts
Primary ContactPraew Kotruchin, Prof
Backup ContactAnne-Laure Cavin, PhD
Outcome results
None listed